Back to mobile site

VistaGen Therapeutics (VTGN) Reports FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder

October 26, 2017 7:41 AM EDT Send to a Friend
VistaGen Therapeutics Inc. (NASDAQ: VTGN) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login